BIO-key International, Inc.

Good morning, everyone. Thank you for standing by, and welcome to the BioKeys International's first quarter of 2026 conference call. During management's prepared remarks, all participants will be in a listen-only mode. Afterwards, listeners will be invited to participate in a question-and-answer session. As a reminder, this conference call is being recorded today, Monday, May 18, 2026. I would now like to turn the call over to Mr. Bill Jones of Investor Relations. You may proceed.

Thank you, Chuck. Hosting today are Biokeys Chairman and CEO, Mike DiPasquale, and its CFO, CeCe Welsh. As a reminder, today's call and webcast, as well as answers to investor questions, include forward-looking statements, which are subject to risks and uncertainties that may cause actual results to differ materially from current expectations. Words such as anticipate, believe, expect, plan, and project, or similar words, identify and express forward-looking statements. Such statements are made based on beliefs, assumptions, and information currently available to management, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act. For a more complete description of risks and uncertainties which affect future performance, please see risk factors in the company's annual report, Form 10-K, as filed with the SEC. Listeners are cautioned not to place undue reliance on forward-looking statements made as of today, and the company makes no obligation to revise or disclose revisions to these statements to reflect circumstances or events occurring after this call. Now, I'll turn the call over to Mike to begin.

Thanks, Bill, and thanks to everyone for joining us today. After my remarks, CC will review the financials and we'll open up the call to investor questions. Our Q1 26 results and Q2 26 outlook reflect the benefit of our team's hard work, particularly over the last year. We're also seeing expanded appreciation for the unparalleled value of that our biometric identity and access management solutions provide in securing mission-critical applications and data. Borrowing the old phrase, BioKey has built a powerful suite of biometric solutions with the belief that customers will come. That strategy is really starting to play out for us in a meaningful way, and I will discuss that. Our Q126 revenues reflect both new customer wins and growing long-term customer deployments in defense and financial services. Last year, we launched our defense and intelligence cybersecurity initiative, targeted primarily in foreign markets for more secure identity and access management solutions. Our customer base now includes several of the world's most prominent and significant defense organizations, and our success in meeting their strategic needs is proving very valuable in supporting new opportunities. But it's not just government, defense, and highly regulated industries. We're also seeing traction with enterprise customers, particularly in EMEA and the EMEA markets. Our progress in these regions is supported by an expanding base of strong regional distribution partners, as well as foreign regulatory frameworks that are favorable to our strong biometric options. Outside of EMEA, we have also added new partners in India and Vietnam where we are seeing solid opportunities in future periods as these partners ramp up their marketing and sales efforts. To better reach public sector opportunities in the U.S., which often require working with a pre-approved vendor, We recently partnered with DLT Solutions, a division of TD Cynics, the world's largest IT distributor and solutions aggregator. TD Cynics employs 23,000 people globally and offers a massive portfolio of IT hardware, software, cybersecurity, and cloud services to over 150,000 customers in more than 100 countries. While DLT is their... kind of public sector arm domestically. We're integrating our portal guard IAM and PASCU biometric solutions into DLT's platform of offerings. The partnership provides a streamlined procurement path, enabling their extensive base of public sector customers to easily purchase and deploy our solutions, many of which face mandates to adopt zero trust digital infrastructure and implement multi-factor authentication. With our solutions, customers can easily meet these requirements and anchor digital access to a person rather than to just a device. We're working closely with the DLT team to help them educate public sector customers on the solutions and compelling ROI that BioKey can provide. On our year-end call, I reviewed several factors that are shaping the market for our solutions today, so I'll just provide a brief overview of those. First, the continued expansion of digital services and mobile use cases that require secure authentication is widening our market opportunity. Second, we believe demand for the secure digital access BioKey uniquely provides will continue to expand as organizations confront a more sophisticated and persistent cybersecurity threat landscape. Third, We expect passwordless authentication to continue to gain traction and become the standard this year and beyond, as enterprises look to reduce risk from phishing, credential reuse, and misuse, as well as account takeover attacks. BioKey enables unique and highly secure passwordless solutions. Fourth, biometric authentication should see growing adoption in the highest value use cases, as we've seen in military, defense, financial services, healthcare, and other highly regulated industries where security and trust are most critical. Fifth, the rise of AI-driven threats really escalates the need for more resilient identity strategies that surpass vulnerable yet widely deployed authentication methods, like phones. And finally, the market is moving towards more unified access platforms that unite workforce, partner, and privileged access under a single flexible foundation. These trends play directly into BioKey strengths, and we are starting to see them in our financial results. Today, our business is predominantly a subscription-based business with recurring revenues. Approximately 50% of our new business comes through our partnership model domestically, and as I've mentioned a number of times before, 100% of our business is sold through channel partners internationally, providing a very, very efficient and, more importantly, scalable model. I also want to mention that we launched a new website in mid-April that is designed to better support our partners and customers in understanding how BioKey can meet their needs. We believe it's an important step to support our growth goals. I want to thank our team who put a lot of hard work and effort into this launch, and I encourage investors to review it at www.biokey.com. And as always, we welcome any feedback that you can provide. From a financial standpoint, BioKey is in a solid position to continue to fund our growth. We ended Q1 with a book value of $7.6 million or approximately $7 a share, including over $2 million or $2.07 per share in cash. And we expect this position to continue to hold or improve as we approach the second quarter, the end of the second quarter. As we mentioned a few days ago, our shares were recently suspended from NASDAQ. Today, we are actively working to return our shares to the NASDAQ capital market and have secured an appeals hearing, which will be held on June 16th, which is next month, about four weeks from tomorrow. In the interim, our shares continue to trade on the OTC markets under the symbol BKYI. Although we cannot be certain of the success or timing of the panel's decision, Our advisors believe there is reason for optimism regarding a return to NASDAQ trading by the summer. In summary, our business is off to a very strong start, and we are confident in our first half outlook and very optimistic regarding the balance of the year and beyond. After years of hard work, we believe BioKey has never been better positioned for growth and improved financial performance. and we will continue to update you, all of our shareholders, on our business and listing process as we proceed forward. With that, I'll turn the call over to CeCe to review the Q1 financial results.